Research programme: polyclonal antibodies - Symphogen/Meiji Seika Kaisha

Drug Profile

Research programme: polyclonal antibodies - Symphogen/Meiji Seika Kaisha

Alternative Names: Sym 006

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meiji Seika Kaisha; Symphogen
  • Developer Meiji Seika Pharma; Symphogen
  • Class Polyclonal antibodies; Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pseudomonal infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pseudomonal-infections in Denmark (Parenteral)
  • 11 Mar 2012 Sym 006 is still in preclinical trials for Pseudomonal infections in Denmark (Parenteral)
  • 04 Dec 2008 Preclinical trials in Pseudomonal infections in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top